Skip to Content

COVID-19 Vaccine Efficacy Higher With Three-Month Interval Between Doses

MONDAY, Feb. 22, 2021 -- A three-month interval between the first and second doses of the ChAdOx1 nCoV-19 Oxford vaccine results in higher vaccine efficacy than a six-week interval, according to a study published online Feb. 19 in The Lancet.

Merryn Voysey, D.Phil., from the University of Oxford in the United Kingdom, and colleagues present data from three single-blind randomized controlled trials and one double-blind study that examined the immunogenicity and protection afforded by the first dose of ChAdOx1 nCoV-19. A total of 24,422 participants were recruited and vaccinated; 17,178 were included in the primary analysis (8,597 received ChAdOx1 nCoV-19 and 8,581 received a control vaccine).

The researchers found that vaccine efficacy was 66.7 percent at more than 14 days after the second dose, with cases in 1.0 and 2.9 percent of participants in the ChAdOx1 nCoV-19 and control groups, respectively. In exploratory analyses, vaccine efficacy after a single vaccine dose was 76.0 percent from day 22 to day 90 after vaccination. During this initial period, protection did not wane, and antibody levels were also maintained, with minimal waning by day 90. Among participants who received two standard doses, efficacy after the second dose was higher in those with a longer prime-boost interval than in those with a short interval (vaccine efficacy: 81.3 percent at 12 weeks or more versus 55.1 percent at less than six weeks).

"Where there is a limited supply, policies of initially vaccinating more people with a single dose may provide greater immediate population protection than vaccinating half the number of people with two doses," a coauthor said in a statement.

The study was partially funded by AstraZeneca.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Read this next

Neurologic Involvement Common in Children Hospitalized With COVID-19

MONDAY, March 8, 2021 -- For children with COVID-19-related hospitalization, neurologic involvement is common and is usually transient, according to a study published online March...

FDA Warns Consumers to Not Use Ivermectin for COVID-19

MONDAY, March 8, 2021 -- The U.S. Food and Drug Administration issued a consumer update last week regarding the use of ivermectin for the treatment and prevention of...

Inflammatory Heart Disease After COVID-19 Rare in Athletes

MONDAY, March 8, 2021 -- Few cases of inflammatory heart disease have been detected among professional athletes who tested positive for COVID-19, according to a study published...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.